Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma

J Clin Oncol. 2023 Nov 10;41(32):4943-4944. doi: 10.1200/JCO.23.01865.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bevacizumab / therapeutic use
  • Brain Neoplasms* / drug therapy
  • Camptothecin / therapeutic use
  • Glioblastoma* / drug therapy
  • Humans
  • Irinotecan / therapeutic use
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • Bevacizumab
  • Irinotecan
  • Camptothecin
  • Angiogenesis Inhibitors